NewLimit
Longevity · United States · Founded 2021 · private
NewLimit raised $435M at a $3.1bn valuation in June 2026 on the strength of a preclinical liver candidate that made old human hepatocytes behave young in mice; its first human trial is planned for 2027.
The record
1 figures · 2 rounds · 5 backers · 3 feed items
Every one of them carries its source, its date, and its age when it has one. Reading the record takes a free account; the account is how you keep a watchlist.